Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages 1250-1255

  Fang, Minggang ^a   Hutchinson, Lloyd ^a   Deng, April ^a   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

BRAF(V600E); Colorectal cancer; Epigenetic silencing; MAFG; Melanoma

Indexed keywords

B RAF KINASE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1; BIOLOGICAL MARKER; BTB PROTEIN; CNC HOMOLOGY 1 PROTEIN; DNA BINDING PROTEIN 8; DNA METHYLTRANSFERASE; HETERODIMER; MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG G PROTEIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; MAFG PROTEIN, HUMAN; TRANSCRIPTION FACTOR MAFG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; DNA BINDING; EPIGENETICS; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; UPREGULATION; COLORECTAL TUMOR; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; PHYSIOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; MAFG TRANSCRIPTION FACTOR; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; REPRESSOR PROTEINS; UP-REGULATION;

EID: 84956615449     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525619113     Document Type: Article

References (26)

1. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11(10):726-734.
2. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148-1159.
3. Hassler MR, Egger G (2012) Epigenomics of cancer - emerging new concepts. Biochimie 94(11):2219-2230.
4. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1):27-36.
5. Toyota M, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96(15):8681-8686.
6. Lao VV, Grady WM (2011) Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 8(12):686-700.
7. De Roock W, Biesmans B, De Schutter J, Tejpar S (2009) Clinical biomarkers in oncology: Focus on colorectal cancer. Mol Diagn Ther 13(2):103-114.
8. Rizzo S, et al. (2010) Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 36(Suppl 3):S56-S61.
9. Tejpar S, et al. (2010) Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15(4):390-404.
10. Dhomen N, Marais R (2007) New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17(1):31-39.
11. Kaneda A, Yagi K (2011) Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci 102(1):18-24.
12. Yagi K, et al. (2010) Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16(1):21-33.
13. Fang M, Ou J, Hutchinson L, Green MR (2014) The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol Cell 55(6):904-915.
14. Muthusamy V, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66(23):11187-11193.
15. Koga Y, et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19(8):1462-1470.
16. Sigalotti L, et al. (2012) Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med 10:185.
17. Thomas NE, et al. (2014) DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res 27(6):1097-1105.
18. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954.
19. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132(3):363-374.
20. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8):3041-3046.
21. Favata MF, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273(29):18623-18632.
22. Fanelli M, Amatori S, Barozzi I, Minucci S (2011) Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. Nat Protoc 6(12):1905-1919.
23. Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1):S4-S11.
24. Esteller M (2006) Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 94(2):179-183.
25. Struhl K (2014) Is DNA methylation of tumour suppressor genes epigenetic? eLife 3:e02475.
26. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR (2007) An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449(7165):1073-1077.